| 62 | 1 | 377 |
| 下载次数 | 被引频次 | 阅读次数 |
目的：分析2价、4价人乳头瘤病毒（HPV）疫苗接种后感染HPV及宫颈病变者感染HPV的亚型分布及相关影响因素。方法：收集2021年1月1日至2022年12月31日在江西省妇幼保健院门诊参加宫颈癌筛查符合HPV疫苗接种条件同时首次确诊HPV检测阳性者，其中既往已接种2价、4价HPV疫苗者551例为试验组，未接种HPV疫苗者9498例为对照组。收集研究对象的临床资料，分析不同临床特征患者高危型HPV亚型感染及宫颈病变构成差异。结果：患者年龄18～45岁，试验组完成疫苗接种计划占81.31%(448/551)。试验组感染HPV亚型前10位为HPV52、HPV16、HPV58、HPV51、HPV39、HPV53、HPV81、HPV54、HPV61和HPV68。对照组感染HPV亚型前10位为HPV52、HPV16、HPV58、HPV53、HPV51、HPV39、HPV18、HPV68、HPV66和HPV56。疫苗型别是接种疫苗后人群感染高危型HPV的影响因素（P<0.05）。试验组与对照组宫颈病变发生率差异有统计学意义（P=0.016）。结论：江西省成年女性接种2价、4价HPV疫苗后HPV52感染最常见，建议接种含HPV52、HPV16等高危型疫苗。接种2价、4价疫苗后患宫颈病变风险降低。接种单剂次HPV疫苗可作为适龄女性的一种选择策略。
Abstract：Objective:To analyze the subtype distribution and related influencing factors of human papillomavirus(HPV)infection after bivalent and quadrivalent HPV vaccination and HPV infection in patients with cervical lesions.Methods:From January 1,2021 to December 31,2022,patients who participated in cervical cancer screening in the outpatient department of Jiangxi Maternal and Child Health Hospital and were diagnosed with positive HPV test for the first time were collected. Among them,551 patients who had been vaccinated with bivalent or quadrivalent HPV vaccines were in the experimental group,and 9498 patients who had not been vaccinated with HPV vaccine were in the control group. The clinical data of the subjects were collected,and the differences of high-risk HPV subtype infection and cervical lesions in patients with different clinical characteristics were analyzed.Results:The patients were aged 18-45 years old,and 81.31%(448/551)of the patients in the experimental group completed the vaccination plan. The top 10 HPV subtypes in the experimental group were HPV52,HPV16,HPV58,HPV51,HPV39,HPV53,HPV81,HPV54,HPV61 and HPV68. The top 10 HPV subtypes in the control group were HPV52,HPV16,HPV58,HPV53,HPV51,HPV39,HPV18,HPV68,HPV66 and HPV56. Vaccine type was associated with high-risk HPV infection after vaccination(P<0.05). There was a significant difference in the incidence of cervical lesions between the experimental group and the control group(P=0.016).Conclusion:HPV52 infection was the most common among adult women in Jiangxi Province after vaccination with bivalent and quadrivalent HPV vaccines. It is recommended to vaccinate high-risk types including HPV52 and HPV16. The risk of cervical lesions was reduced after vaccination of bivalent and quadrivalent vaccines. Vaccination with a single dose of HPV vaccine can be an option for women of appropriate age.
[1] Rahangdale L,Mungo C,O'Connor S,et al. Human papillomavirus vaccination and cervical cancer risk[J].BMJ,2022,379:e070115.
[2] Falcaro M,Casta?on A,Ndlela B,et al. The effects of the national HPV vaccination programme in England,UK,on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence:a register-based observational study[J]. Lancet,2021,398(10316):2084-2092.
[3] Kavanagh K,Pollock KG,Cuschieri K,et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland:a 7-year cross-sectional study[J]. Lancet Infect Dis,2017,17(12):1293-1302.
[4]韦梦娜，余艳琴，徐慧芳，等.中国大陆地区不同宫颈病变人群中人乳头瘤病毒感染率及型别分布的系统研究[J].中国肿瘤临床与康复，2020,27(2):133-137.
[5]王月云，林威，吴波，等. 2014-2016年深圳市子宫颈癌筛查中HPV阳性者HPV高危亚型分布及相关因素[J].中华预防医学杂志，2018,52(5):480-485.
[6]肖松舒，范洁琳，贺斯黎，等. 16320例妇科门诊患者HPV感染情况分析[J].中南大学学报（医学版），2015,40(4):373-379.
[7]郑子雯，李凌，李隆玉，等.农村地区以人群为基础的子宫颈癌筛查中HPV初筛不同分流方法效果的初步评价[J].中国妇产科临床杂志，2018,19(6):508-511.
[8] Lei J,Ploner A,Elfstr?m KM,et al. HPV vaccination and the risk of invasive cervical cancer[J]. N Engl J Med,2020,383(14):1340-1348.
[9] Zhao FH,Lewkowitz AK,Hu SY,et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China:a pooled analysis of 17 populationbased studies[J]. Int J Cancer,2012,131(12):2929-2938.
[10] Pinto LA,Viscidi R,Harro CD,et al. Cellular immune responses to HPV-18，-31,and-53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles[J]. Virology,2006,353(2):451-462.
[11] Schiller JT,CastellsaguéX,Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines[J]. Vaccine,2012,30 Suppl 5(0 5):F123-F138.
[12] Brisson M,Kim JJ,Canfell K,et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination:a comparative modelling analysis in 78 lowincome and lower-middle-income countries[J]. Lancet,2020,395(10224):575-590.
[13] CastellsaguéX. Natural history and epidemiology of HPV infection and cervical cancer[J]. Gynecol Oncol,2008,110(3 Suppl 2):S4-7.
[14] Paavonen J,Naud P,Salmerón J,et al. Efficacy of human papillomavirus(HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types(PATRICIA):final analysis of a double-blind,randomised study in young women[J].Lancet,2009,374(9686):301-314.
[15] Committee on Adolescent Health Care Immunization Expert Work Group. Committee Opinion No. 704:Human Papillomavirus Vaccination[J]. Obstet Gynecol,2017,129(6):e173-e178.
[16]中华医学会妇科肿瘤学分会，中国优生科学协会阴道镜和宫颈病理学分会.人乳头瘤病毒疫苗临床应用中国专家共识[J].中国医学前沿杂志（电子版），2021,13(2):1-12.
[17] Zeng Z,Yang H,Li Z,et al. Prevalence and genotype distribution of HPV infection in China:analysis of 51,345 HPV genotyping results from China's largest CAP certified laboratory[J]. J Cancer,2016,7(9):1037-1043.
[18] Na J,Li Y,Wang J,et al. The correlation between multiple HPV infections and the occurrence,development,and prognosis of cervical cancer[J]. Front Microbiol,2023,14:1220522.
[19] Malagón T,Drolet M,Boily MC,et al. Cross-protective efficacy of two human papillomavirus vaccines:a systematic review and meta-analysis[J]. Lancet Infect Dis,2012,12(10):781-789.
[20] Basu P,Malvi SG,Joshi S,et al. Vaccine efficacy against persistent human papillomavirus(HPV)16/18 infection at 10 years after one,two,and three doses of quadrivalent HPV vaccine in girls in India:a multicentre,prospective,cohort study[J]. Lancet Oncol,2021,22(11):1518-1529.
[21]文天萌，由婷婷，潘程浩，等.全球单剂次预防性人乳头瘤病毒疫苗接种研究进展及应用现状[J].中华肿瘤防治杂志，2023,30(20):1201-1207.
[22] Carozzi F,Puliti D,Ocello C,et al. Monitoring vaccine and non-vaccine HPV type prevalence in the postvaccination era in women living in the Basilicata region,Italy[J]. BMC Infect Dis,2018,18(1):38.
基本信息:
中图分类号:R737.33
引用信息:
[1]姚心雨,胡小青,袁建晖,等.江西省成年女性接种2价、4价HPV疫苗后感染HPV亚型分布及宫颈病变构成分析[J].广州医科大学学报,2025,53(02):34-39.
基金信息:
江西省科技厅基金项目（20212BAG70008）
2025-04-15
2025-04-15